Psilocybin, the psychoactive compound from magic mushrooms, is being used to treat depression and anxiety in terminally ill patients in a new trial at Melbourne’s St Vincent’s Hospital.
Prestigious international institutions have initiated robust psychedelic research programs. Does Australia risk being left behind if it doesn’t do the same?
New research published in the Australian Psychologist Journal claims Australia is missing out on the benefits of using psychedelic drugs to treat a range of mental health illnesses.
On 9th April 2018 The Project (Channel Ten) interviewed PRISM co-founders Dr Stephen Bright and Steve McDonald about the need for Australia to embrace formal research into psychedelic medicines.
In a press release dated 26 August 2017, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the US Food and Drug Administration has granted ‘Breakthrough [...]
Scientists believe the illegal drug MDMA, also known as ecstasy, has an untapped potential to treat post-traumatic stress disorder (PTSD). But they say plans to test the drug on war veterans in [...]
PRISM is a proud sponsor of the Entheogenesis Australis 2017 Outdoor Psychedelic Symposium. For over a decade Entheogenesis Australis has provided a major meeting place for ethnobotanical [...]
This presentation was delivered by PRISM Vice-President Dr Stephen Bright at a fundraising seminar and dinner held at The Melbourne Brain Centre, Parkville on 8th April 2016.
This presentation was delivered by PRISM President Dr Martin Williams at a fundraising seminar and dinner held at The Melbourne Brain Centre, Parkville on 8th April 2016.
MDMA — more commonly known as ecstasy — is one step closer to becoming a legal form of treatment for post-traumatic stress disorder (PTSD) in the United States.
In September 2016 PRISM’s Vice President Dr Stephen Bright spoke at Beyond Psychedelics, a global multidisciplinary psychedelic forum held in Prague, Czech Republic.
When Martin Williams’ research plan was first rejected by an ethics committee in 2012, he understood why. The medicinal chemistry researcher could see some valid sticking points.
Some drugs that have therapeutic benefits are banned because of emerging patterns of use that do not conform to dominant paradigms. Such policies are often driven by morality rather than evidence.
ABC Radio National’s program The Drawing Room recently interviewed PRISM’s Steve McDonald and Ridiculusmus Artistic Director David Woods about MDMA-therapy to treat posttraumatic stress
In April 2014 PRISM’s President Martin Williams and Vice President Stephen Bright were invited to join a panel discussion at the Melbourne screening of Neurons to Nirvana,
As UK researchers begin human therapeutic experiments using the psychedelic drug LSD an Australian group are setting up the nation’s first clinical study using MDMA